RCUS — Arcus Biosciences Share News
0.000.00%
Last trade - 00:00- $2.91bn
- $2.30bn
- $247.00m
Brief: Arcus Biosciences Inc - Discontinues Phase 3 Star-121 Study With Gilead Due To Futility
Brief: Arcus Biosciences Files For Mixed Shelf
Arcus Biosciences Q4 revenue falls, net loss widens
Brief: Arcus Biosciences Q4 Operating Expenses USD 147 Million
Brief: Arcus Outlines Plans For Casdatifan And Its Inflammation Programs
U.S. STOCKS ON THE MOVE-GE Aerospace
U.S. STOCKS ON THE MOVE-EastGroup, Boeing, Exxon Mobil
U.S. STOCKS ON THE MOVE-ProPetro, Nvidia, Citigroup
Arcus falls after co and Gilead scrap late-stage trial of cancer drug combo
Gilead, Arcus scrap late-stage trial of cancer drug combo (updated)
Brief: Arcus Provides Update On Phase 3 STAR-221 Study And Concentrates Its Research And Development Investment On Casdatifan And Emerging Inflammation And Immunology Portfolio
Gilead, Arcus scrap late-stage trial of cancer drug combo
U.S. STOCKS ON THE MOVE-Dominion Energy, Reddit, Brighthouse Financial
U.S. STOCKS ON THE MOVE-Dominion Energy, Reddit, Western Digital
U.S. STOCKS ON THE MOVE-Apple, First Solar, Reddit
Arcus Biosciences falls after $250 mln stock sale
Brief: Arcus Biosciences Says It Announces Pricing Of $250 Million Public Offering Of Common Stock
Arcus Biosciences falls on stock offering launch
Brief: Arcus Biosciences Reports Third-Quarter 2025 Financial Results And Provides A Pipeline Update